Bisantrene
- Generic Name
- Bisantrene
- Drug Type
- Small Molecule
- Chemical Formula
- C22H22N8
- CAS Number
- 78186-34-2
- Unique Ingredient Identifier
- 39C34M111K
A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS
Phase 1
Withdrawn
- Conditions
- Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaHigher Risk Myelodysplastic SyndromeChronic Myelomonocytic Leukemia
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Race Oncology Ltd
- Registration Number
- NCT05456269
- Locations
- 🇦🇺
Calvary Mater, Newcastle, New South Wales, Australia
Bisantrene Combination for Resistant AML
Phase 2
Recruiting
- Conditions
- Myelogenous Leukemia, Acute
- Interventions
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 29
- Registration Number
- NCT04989335
- Locations
- 🇮🇱
Chaim Sheba Medical Center, Ramat Gan, Israel
Bisantrene for Relapsed /Refractory AML
Phase 2
Completed
- Conditions
- Acute Myelogenous LeukemiaAllogeneic Stem Cell Transplantation
- Interventions
- First Posted Date
- 2019-01-29
- Last Posted Date
- 2020-08-07
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT03820908
- Locations
- 🇮🇱
Chaim Sheba Medical Center, Ramat Gan, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath